Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 315

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 315
---
On April 23, 2025, the Company announced that, in alignment with both company's current strategic priorities, Sanofi and Innate agreed to terminate the 2016 Agreement as it relates to SAR’579/IPH6101 (CD123 ANKET), effective as of June 30, 2025. Innate will regain the rights on July 1, 2025. Sanofi and Innate will discuss a transition plan with regard to ongoing studies.

IPH6401/SAR’514

During 2022 first semester, th e Company was informed of Sanofi's decision to advance IPH6401/SAR’514 towards regulatory preclinical studies aimed at studying an investigational new drug. As such, Sanofi has selected a second multi-specific antibody that engages NK cells as a drug candidate. This selection triggered a € 3.0 2.0OnMarch 27, 2025, t he Company announced that the clinical study will be terminated early as Sanofi will now pursue development of IPH6401/SAR’514 in autoimmune indications.

Refer to Notes 2. p and 13 for accounting description.

Collaboration and research license agreement with Sanofi signed in 2022

On December 19, 2022, the Company announced that it had entered into a research collaboration and license agreement with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (“ Sanofi”) pursuant to which the Company granted Sanofi an exclusive license on the Innate Pharma's B7H3 ANKET® program and options on two

Under the terms of the research collaboration and license agreement, the Company was eligible for an initial payment of € 25.0 1.35

F-17

The Company considers that the license to the B7-H3 technology is a right to use the intellectual property granted exclusively to Sanofi from the effective date of the agreement.

Under the terms of this agreement, the Company has also granted two three years two

On December 19, 2023, the Company announced that Sanofi had exercised one two® platform, triggering a milestone payment of € 15.0® platform, currently under development in solid tumors. Termination was effective at the end of a 90

The Company will also provide collaborative research services to Sanofi for an agreed period, extendable by mutual agreement. During this period, Sanofi and Innate will collaborate and work on research activities defined in a contractual work program.

Under the terms of the agreement